• 1
    Fiore M., Jaén C., Baker T., Benowitz N., Curry S., Dorfman S. et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services; Public Health Service; 2008.
  • 2
    West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299303.
  • 3
    Shiffman S., Sweeney C. T., Ferguson S. G., Sembower M. A., Gitchell J. G. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther 2008; 30: 18528.
  • 4
    Lam T. H., Abdullah A. S., Chan S. S., Hedley A. J. Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigation. Psychopharmacology 2005; 177: 4008.
  • 5
    Burns E. K., Levinson A. H. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. Am J Prev Med 2008; 34: 2125.
  • 6
    Wiggers L. C., Smets E. M., Oort F. J., Storm-Versloot M. N., Vermeulen H., Van Loenen L. B. et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med 2006; 13: 7988.
  • 7
    Peters E. N., Hughes J. R. The day-to-day process of stopping or reducing smoking: a prospective study of self-changers. Nicotine Tob Res 2009; 11: 108392.
  • 8
    Shiffman S., Scharf D. M., Shadel W. G., Gwaltney C. J., Dang Q., Paton S. M. et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol 2006; 74: 27685.
  • 9
    Kenford S. L., Fiore M. C., Jorenby D. E., Smith S. S., Wetter D., Baker T. B. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994; 271: 58994.
  • 10
    Westman E. C., Behm F. M., Simel D. L., Rose J. E. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 1997; 157: 33540.
  • 11
    Pfizer Inc. Nicotrol® NS (Nicotine Nasal Spray) (Prescribing Information). New York: Pfizer Inc. 2010. Available at: 2010. (accessed 14 June 2010). (Archived by Webcite® at
  • 12
    Pfizer Inc. Nicotrol® Inhaler (Nicotine Inhalation System) (Prescribing Information). New York: Pfizer Inc. 2008. Available at: 2008. (accessed 14 June 2010). (Archived by Webcite® at
  • 13
    National Institute for Health and Clinical Excellence. NICE Public Health Guidance 10: Smoking Cessation Services in Primary Care, Pharmacies, Local Authorities and Workplaces, Particularly for Manual Working Groups, Pregnant Women and Hard to Reach Communities. London: National Institute for Health and Clinical Excellence. 2008. Available at: 2008. (accessed 14 June 2010). (Archived by Webcite® at
  • 14
    Dale L. C., Glover E. D., Sachs D. P., Schroeder D. R., Offord K. P., Croghan I. T. et al. Bupropion for smoking cessation: predictors of successful outcome. Chest 2001; 119: 135764.
  • 15
    Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 1997. Morb Mortal Wkly Rep 1999; 48: 9936.
  • 16
    Borrelli B., Papandonatos G., Spring B., Hitsman B., Niaura R. Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men. Addiction 2004; 99: 37885.
  • 17
    Pfizer Inc. Chantix® (Varenicline) Tablets (Highlights of Prescribing Information). New York: Pfizer Inc. April 2010. Available at: 2009. (accessed 14 June 2010). (Archived by Webcite® at
  • 18
    Hughes J. R., Keely J. P., Niaura R. S., Ossip-Klein D. J., Richmond R. L., Swan G. E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 1325.
  • 19
    West R., McEwen A., Bolling K., Owen L. Smoking cessation and smoking patterns in the general population: a 1-year follow-up. Addiction 2001; 96: 891902.
  • 20
    Hajek P., Tønnesen P., Arteaga C., Russ C., Tonstad S. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 2009; 104: 1597602.
  • 21
    Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B. et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 4755.
  • 22
    Jorenby D. E., Hays J. T., Rigotti N. A., Azoulay S., Watsky E. J., Williams K. E. et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 5663.
  • 23
    Gonzales D. H., Nides M. A., Ferry L. H., Kustra R. P., Jamerson B. D., Segall N. et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69: 43844.
  • 24
    National Cancer Institute. Clearing the Air: Quit Smoking Today. NIH Publication 08-1647. Washington, DC: National Institutes of Health. Available at: (accessed 14 June 2010). (Archived by Webcite® at
  • 25
    Fiore M. C. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45: 11969.
  • 26
    Nides M., Glover E. D., Reus V. I., Christen A. G., Make B. J., Billing C. B. Jr et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32: 66475.
  • 27
    Fagerström K. O., Schneider N. G. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989; 12: 15982.
  • 28
    Tonstad S., Tønnesen P., Hajek P., Williams K. E., Billing C. B., Reeves K. R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 6471.
  • 29
    Hays J. T., Hurt R. D., Rigotti N. A., Niaura R., Gonzales D., Durcan M. J. et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 2001; 135: 42333.
  • 30
    GlaxoSmithKline. Zyban® (Bupropion Hydrochloride) Sustained-Release Tablets (Prescribing Information). Research Triangle Park, NC: GlaxoSmithKline. 2009. Available at: (accessed 14 June 2010). (Archived by Webcite® at
  • 31
    Heffner J. L., Lee T. C., Arteaga C., Anthenelli R. M. Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials. Drug Alcohol Depend 2010; 109: 1205.
  • 32
    Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C. et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195202.
  • 33
    Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 68591.
  • 34
    Ward M. M., Swan G. E., Jack L. M. Self-reported abstinence effects in the first month after smoking cessation. Addict Behav 2001; 26: 31127.
  • 35
    Ockene J. K., Emmons K. M., Mermelstein R. J., Perkins K. A., Bonollo D. S., Voorhees C. C. et al. Relapse and maintenance issues for smoking cessation. Health Psychol 2000; 19: 1731.